您的位置:山东大学 -> 科技期刊社 -> 《山东大学学报(医学版)》

山东大学学报(医学版) ›› 2016, Vol. 54 ›› Issue (1): 52-57.doi: 10.6040/j.issn.1671-7554.0.2015.1042

• 临床医学 • 上一篇    下一篇

PI3K/AKT及其相关因子在结肠癌中的表达

张雪群1,高卫2,潘盼3,高骏逸4   

  1. 1.泰山医学院研究生院, 山东 泰安 271016;
    2.山东大学附属济南市中心医院肿瘤科, 山东 济南 250013;
    3.山东大学附属济南市中心医院病理科, 山东 济南 250013;
    4.潍坊医学院, 山东 潍坊 261053
  • 收稿日期:2015-10-30 出版日期:2016-01-11 发布日期:2016-01-11
  • 通讯作者: 髙卫. E-mail:gjygw-1994@163.com E-mail:gjygw-1994@163.com
  • 基金资助:
    山东省科技发展计划(2014GSF118008)

The expressions of PI3K/AKT and its related factors in colon cancer

ZHANG Xuequn1, GAO Wei2, PAN Pan3, GAO Junyi4   

  1. 1. Graduate School of Taishan Medical College, Taian 271016, Shandong, China;
    2. Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, China;
    3. Department of Pathology, Jinan Central Hospital Affiliated to Shandong University, Jinan 250013, Shandong, China;
    4. Weifang Medical College, Weifang 261053, Shandong, China
  • Received:2015-10-30 Online:2016-01-11 Published:2016-01-11

摘要: 目的 探讨PI3K/AKT信号通路中相关细胞因子PI3Kp110α、p-AKTser473、p-mTORser2448、CyclinD1在结肠癌组织中的表达及其与临床各病理参数之间的关系。 方法 采用免疫组织化学法检测65例结肠癌组织(结肠癌组)和15例结肠腺瘤组织(结肠腺瘤组)的PI3Kp110α、p-AKTser473、p-mTORser2448、CyclinD1的表达,分析各指标在结肠癌组的表达与临床各病理参数之间的关系。 结果 PI3Kp110α、p-AKTser473、p-mTORser2448、CyclinD1在结肠癌组中的阳性表达率均显著高于结肠腺瘤组,差异均有统计学意义(P<0.05)。PI3Kp110α、p-AKTser473、p-mTORser2448在结肠癌组的表达与性别、年龄、分化程度、是否淋巴结转移及TNM分期之间差异无统计学意义(P>0.05)。CyclinD1在不同分化程度及不同TNM分期的结肠癌组织中的表达有统计学差异(P<0.05),在不同性别、年龄及是否有淋巴结转移之间无明显差异(P>0.05)。PI3Kp110α、 p-AKTser473、p-mTORser2448、CyclinD1在结肠腺瘤组的阳性表达与性别、年龄、分化程度、是否淋巴结转移及TNM分期之间无统计学差异(P>0.05)。 结论 PI3Kp110α、 p-AKTser473、p-mTORser2448、CyclinD1的表达与结肠癌的发生发展密切相关,对结肠癌的预后评估及新靶点的研发具有重要意义。

关键词: 磷脂酰肌醇3激酶p110α, 磷酸化哺乳动物雷帕霉素靶蛋白ser2448, 细胞周期蛋白D1, 结肠癌, 磷酸化蛋白激酶B ser473

Abstract: Objective To investigate the expressions of PI3K/AKT signaling pathway and its related factors(PI3Kp110α, p-AKTser473, p-mTORser2448, CyclinD1)in colon cancer and their association with other clinical pathological parameters. Methods The expressions of PI3Kp110α, p-AKTser473, p-mTORser2448 and CyclinD1 were detected with immunohistochemical method in 65 cases of colon cancer(colon cancer group), and 15 cases of colonic adenoma(colonic adenoma group). The association between the expressions and clinical pathological parameters were analyzed. Results The positive expressions of PI3Kp110α, p-AKTser473, p-mTORser2448 and CyclinD1 were significantly higher in colon cancer than in colonic adenoma(all P<0.05). In the colon cancer group, there were no differences in the expressions of PI3Kp110α, p-AKTser473 and p-mTORser2448 between different genders, ages, different degrees of differentiation, lymph node metastasis and TNM staging(all P>0.05); while there were differences in the expression of CyclinD1 between varying degrees of differentiation and TNM staging(all P<0.05), but no statistical differences between different genders, ages and different degrees of lymph node metastasis(all P>0.05). In the 山 东 大 学 学 报 (医 学 版)54卷1期 -张雪群,等.PI3K/AKT及其相关因子在结肠癌中的表达 \=-colonic adenoma, there were no differences in the expressions of PI3Kp110α, p-AKTser473、 p-mTORser2448 and CyclinD1 between different genders, ages, degrees of differentiation, lymph node metastasis and TNM staging(all P>0.05). Conclusion The expressions of PI3Kp110α, p-AKTser473, p-mTORser2448 and CyclinD1 are closely related with the occurrence and development of colon cancer, playing a significant role in the prognosis of colon cancer and new research targets.

Key words: p-AKTser473, p-mTORser2448, Colon cancer, PI3Kp110α, CyclinD1

中图分类号: 

  • R735.3
[1] Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012[J]. CA Cancer J Clin, 2012, 62(4):220-241.
[2] Jemal A, Bray F, Center MM, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2):69-90.
[3] Ward E, Hao Y, Xu J. Cancer statistics[J]. CAJ Cancer Clin, 2009, 59(4):225-249.
[4] Siegel R, Naishadham D, Jemal A. Cancer statistics[J]. CAJ Clin, 2013, 63(1):11-30.
[5] Ward SG, Finan P. Isoform-specific phosphoinositide 3-kinase inhibitors as therapeutic agents[J]. Curr Opin Pharmacol, 2003, 3(4):426-434.
[6] Pene F, Claessens YE, Muller O, et a1. Role of the Dhosphatidylinositol 3-kinase/Akt and mT0R/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma[J]. Oncogene, 2002, 2l(43):6587-6597.
[7] Rychahou PG, Murillo CA, Evers BM. Targeted RNA interference of PI3K pathway components sensitizes colon cancer cells to TNF-related apoptosis-inducing ligand(TRAIL)[J]. Surgery, 2005, 138(2):391-397.
[8] Shao J, Washington MK, Saxena R, et al. Heterozygous disruption of the PTEN promotes intestinal neoplasia in APC min/+mouse roles of osteopontin[J]. Carcinogenesis, 2007, 28(12):2476-2483.
[9] Ellis L, Ku SY, Ramakrishnan S, et al. Combinatorial antitumor effect of HDAC and the PI3K -Akt -mTOR pathway inhibition in a Pten deficient model of prostate cancer[J]. Oncotarget, 2013, 27(5):122-135.
[10] Hales EC, Taub JW, Matherly LH, et al. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis:Targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia[J]. Cell Signal, 2014, 26(1):149-161.
[11] Yentrapalli R, Azimzadeh O, Sriharshan A, et al. The PI3K/Akt/mTOR pathway is implicated in the premature senescence of primary human endothelial cells exposed to chronic radiation[J]. PLoS One, 2013, 11(1):181-226.
[12] Slattery ML, Herrick JS, Lundgreen A, et al. Genetic variation in a metabolic signaling pathway and colon and rectal cancer risk:mTOR, PTEN, STK11, RPKAA1, PRKAG2, TSC1, TSC2, PI3K and Akt1[J]. Carcinogenesis, 2010, 31(9):1604-1611.
[13] 彭秋平, 梁后杰, 边志衡, 等. mTOR信号通路调控HK-Ⅱ表达对结肠癌细胞增殖的影响[J]. 现代肿瘤医学, 2007, 15(6):760-762.
[14] 李宝秀, 李春燕, 刘国龙, 等. 雷帕霉素靶蛋白在ⅢB期结肠癌中的异常表达及其意义[J]. 解放军医学杂志, 2010, 35(8):961-965.
[15] Johnson SM, Gulhati P, Rampy BA, et al. Novel expression patterns of PI3K/Akt/mTOR signaling pathway components in colorectal cancer[J]. J Am Coll Surg, 2010, 210(5):767-776.
[16] Cheung M, Testa JR. Diverse mechanisms of AKT pathway activation in human malignancy[J]. Curr Cancer Drug Targets, 2013, 13(3):234-244.
[17] Viglietto G, Motti ML, Bruni P, et al. Cytoplasmic relocalization and inhibition of the cyclin- dependent kinase inhibitor p27(Kip1)by PKB/Akt-mediated phosphorylation in breast cancer[J]. Nat Med, 2002, 8(10):1136-1144.
[18] Gao N, Zhang Z, Jiang BH, et al. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K /AKT /mTOR /p70S5K1 signaling in human ovarian cancer cells[J]. Am J Physiol Cell Physiol, 2004, 287(2):281-291.
[19] Hua KQ, Feng WW, Cao Q, et al. Estrogen and progestin regulate metastasis through the PI3K /AKT pathway in human ovarian cancer[J]. Int J of Oncology, 2008, 33(5):959-967.
[20] Morsaki T, Uchiyam A, Yuzuki D, et al. Interleukin 4 regulates G1 cell progression in colorectal carcinoma cell[J]. Cancer Res, 2004, 54(4):1113-1118.
[21] 陈小贺, 孟文格, 孟繁杰, 等. CyclinD1、CDK4和Rb在大肠癌中的表达及意义[J]. 肿瘤防治研究, 2006, 33(6):428-430.
[1] 刘惠苓,王兴文,冯少滨,冯虹,韩俊庆. B类I型清道夫受体的高表达与结肠癌患者预后的相关性[J]. 山东大学学报(医学版), 2017, 55(10): 84-89.
[2] 王贲士, 单军奇,侯庆生,公为鹏,朱振宇,郭洪亮. CD11b+/CD66b-表型髓系细胞在结肠癌进展和肝转移中的作用[J]. 山东大学学报(医学版), 2017, 55(10): 41-45.
[3] 王尧, 陈艳红, 陈宏. 结肠癌患者外周血DPYD基因多态性与5-FU敏感性和毒副作用相关性分析[J]. 山东大学学报(医学版), 2014, 52(S1): 18-21.
[4] 仇会会1,叶丽平1,温有锋2,李丹1,宋佳1. IL-6对卵巢癌细胞bcl-2、cyclinD1和VEGF表达的影响[J]. 山东大学学报(医学版), 2014, 52(6): 17-21.
[5] 孟宪鹏1,刘杰2,苏娅3,邴雪4,高卫2. SU11274对人结肠癌LOVO细胞裸鼠移植瘤的抑制作用[J]. 山东大学学报(医学版), 2014, 52(2): 20-24.
[6] 李雪梅1, 颜世平1, 宿敬然2,程兆令1, 朱强1. TIPE2在结肠癌发展中的作用及分子机制[J]. 山东大学学报(医学版), 2014, 52(1): 20-22.
[7] 孙秀梅1,高峰2,刘子凤3. 盐霉素对结肠癌干细胞特性的抑制作用[J]. 山东大学学报(医学版), 2013, 51(9): 40-44.
[8] 任鹏1,郝青2,王杰书3,李洪林3,李波3,王峰3. 趋化因子受体3及血管生成拟态在结肠癌肝转移中的作用[J]. 山东大学学报(医学版), 2012, 50(8): 96-99.
[9] 李万全1,朱晓林2,于成功2. 丁酸钠对HT-29结肠癌细胞增殖及ICAM-1表达的影响[J]. 山东大学学报(医学版), 2010, 48(11): 70-.
[10] 马岚青1,郭永章2,张洪斌2,珠珠2,陈明清3,段丽平1. RNA干扰对小鼠结肠癌细胞VEGF表达及细胞增殖的影响[J]. 山东大学学报(医学版), 2010, 48(11): 63-69.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!